The incidence and risk factors for venous thromboembolism in adolescent and young adult oncology patients.
adolescent/young adult oncology
oncology
risk factors
thrombotic disorders
venous thromboembolism
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
revised:
17
01
2021
received:
05
08
2020
accepted:
21
01
2021
pubmed:
25
2
2021
medline:
15
10
2021
entrez:
24
2
2021
Statut:
ppublish
Résumé
Venous thromboembolism (VTE) is a known complication among pediatric and adult cancer patients. Adolescent and young adult oncology (AYAO) patients have unique biological and physiological characteristics that make them distinct from other populations. Our objective was to study the VTE incidence, risk factors, and outcomes, which have been understudied in this population. A retrospective case-control study was conducted on AYAO participants with new or relapsed cancer and an imaging confirmed VTE from January 2011 to November 2016 at our institution. Eligible AYAO participants without a history of VTE were designated as controls and were randomly selected from our institution's tumor registry. Demographics, medical history, surgeries, central venous catheter (CVC) data, VTE diagnosis and treatment, relapses, and deaths were abstracted. Thirty-five VTE cases and 70 controls were included in this analysis. Eighty percent of cases had leukemia or lymphoma (vs. a solid tumor) compared to 58% of controls. The majority of VTEs (57%) were CVC associated, and more than 70% of cases had more than one CVC placed during their cancer treatment versus 34% of controls. Infection was associated with increased VTE risk (OR = 6.35, 95% CI = 2.30, 17.55, p < .0001). VTE cases had increased cancer relapse (23% vs. 10%) and mortality rates (29% vs. 16%) than controls. AYAO participants with a VTE were more likely to have leukemia or lymphoma, more than one CVC or infection. Further studies are needed to identify patients who would benefit from modifiable prevention measures, such as limiting to one CVC, preventing infections, or considering prophylactic anticoagulation for those with a liquid tumor.
Sections du résumé
BACKGROUND
Venous thromboembolism (VTE) is a known complication among pediatric and adult cancer patients. Adolescent and young adult oncology (AYAO) patients have unique biological and physiological characteristics that make them distinct from other populations. Our objective was to study the VTE incidence, risk factors, and outcomes, which have been understudied in this population.
PROCEDURE
A retrospective case-control study was conducted on AYAO participants with new or relapsed cancer and an imaging confirmed VTE from January 2011 to November 2016 at our institution. Eligible AYAO participants without a history of VTE were designated as controls and were randomly selected from our institution's tumor registry. Demographics, medical history, surgeries, central venous catheter (CVC) data, VTE diagnosis and treatment, relapses, and deaths were abstracted.
RESULTS
Thirty-five VTE cases and 70 controls were included in this analysis. Eighty percent of cases had leukemia or lymphoma (vs. a solid tumor) compared to 58% of controls. The majority of VTEs (57%) were CVC associated, and more than 70% of cases had more than one CVC placed during their cancer treatment versus 34% of controls. Infection was associated with increased VTE risk (OR = 6.35, 95% CI = 2.30, 17.55, p < .0001). VTE cases had increased cancer relapse (23% vs. 10%) and mortality rates (29% vs. 16%) than controls.
CONCLUSION
AYAO participants with a VTE were more likely to have leukemia or lymphoma, more than one CVC or infection. Further studies are needed to identify patients who would benefit from modifiable prevention measures, such as limiting to one CVC, preventing infections, or considering prophylactic anticoagulation for those with a liquid tumor.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e28957Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Tricoli JV, Bleyer A. Adolescent and young adult cancer biology. Cancer J. 2018;24(6):267-274.
National Cancer Institute. Adolescents and Young Adults with Cancer. Published 2018. https://www.cancer.gov/types/aya. Accessed 2020.
O'brien SH, Klima J, Termuhlen AM, Kelleher KJ. Venous thromboembolism and adolescent and young adult oncology inpatients in US children's hospitals, 2001 to 2008. J Pediatr. 2011;159(1):133-137.
Raffini L, Huang Y-S, Witmer C, Feudtner C. Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007. Pediatrics. 2009;124(4):1001-1008.
Athale U, Siciliano S, Thabane L, et al. Epidemiology and clinical risk factors predisposing to thromboembolism in children with cancer. Pediatr Blood Cancer. 2008;51(6):792-797.
Monagle P, Adams M, Mahoney M, et al. Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry. Pediatr Res. 2000;47(6):763-766.
Cooper JD, Costello AG, Shaw PH. A comparison of extremity thrombosis rates in adolescent and young adult versus younger pediatric oncology patients at a children's hospital. J Adolesc Young Adult Oncol. 2017;6(1):62-66.
Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013;119(3):648-655.
Athale UH, Mizrahi T, Laverdiere C, et al. Impact of baseline clinical and laboratory features on the risk of thrombosis in children with acute lymphoblastic leukemia: a prospective evaluation. Pediatr Blood Cancer. 2018;65(5):e26938.
Journeycake JM, Buchanan GR. Catheter-related deep venous thrombosis and other catheter complications in children with cancer. J Clin Oncol. 2006;24(28):4575-4580.
Caruso V, Iacoviello L, Di Castelnuovo A, et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood. 2006;108(7):2216-2222.
Khorana AA, Dalal MR, Lin J, Connolly GC. Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States. Clinicoecon Outcomes Res. 2013;5:101-108.
Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2020;38(5):496-520.
Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902-4907.
Al-Ogaili A, Fuentes HE, Tafur AJ, Caprini J. Risk assessment as a guide for the prevention of cancer-associated thromboembolism. Int Angiol. 2018;37(4):269-276.
Bell AD, Hockenberry M, Landier W, Ewing N. Venous thromboembolism risk assessment and prophylaxis use in pediatric, adolescent, and young adult hematology oncology patients. J Pediatr Hematol Oncol. 2015;37(6):455-458.
Meier KA, Clark E, Tarango C, Chima RS, Shaughnessy E. Venous thromboembolism in hospitalized adolescents: an approach to risk assessment and prophylaxis. Hosp Pediatr. 2015;5(1):44-51.
Tullius BP, Athale U, Van Ommen CH, Chan AKC, Palumbo JS, Balagtas JMS. The identification of at-risk patients and prevention of venous thromboembolism in pediatric cancer: guidance from the SSC of the ISTH. J Thromb Haemost. 2018;16(1):175-180.
Foo R, Fujii A, Harris Jo-A, Lamorte W, Moulton S. Complications in tunneled CVL versus PICC lines in very low birth weight infants. J Perinatol. 2001;21(8):525-530.
Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.
CDC. Healthy Weight, Nutrition, and Physical Activity. About Child & Teen BMI. https://www.cdc.gov/healthyweight/assessing/bmi/childrens_bmi/about_childrens_bmi.html. Accessed October 25, 2020.
Stata Statistical Software [computer program]. College Station, TX; 2020.
Raffini L, Trimarchi T, Beliveau J, Davis D. Thromboprophylaxis in a pediatric hospital: a patient-safety and quality-improvement initiative. Pediatrics. 2011;127(5):e1326-e1332.
Prentiss AS. Early recognition of pediatric venous thromboembolism: a risk-assessment tool. Am J Crit Care. 2012;21(3):178-183.quiz 184.
Rühle F, Stoll M. Advances in predicting venous thromboembolism risk in children. Br J Haematol. 2018;180(5):654-665.
Mandel-Shorer N, Tzvi-Behr S, Harvey E, Revel-Vilk S. Central venous catheter-related venous thrombosis in children with end-stage renal disease undergoing hemodialysis. Thromb Res. 2018;172:150-157.
Jaffray J, Witmer C, O'brien SH, et al. Peripherally inserted central catheters lead to a high risk of venous thromboembolism in children. Blood. 2020;135(3):220-226.
Carrillo LA, Kumar A, Harting MT, Pedroza C, Cox CS. Venous thromboembolism risk factors in a pediatric trauma population. Pediatr Surg Int. 2019;35(4):487-493.
Tran M, Shein SL, Ji X, Ahuja SP. Identification of a "VTE-rich" population in pediatrics - critically ill children with central venous catheters. Thromb Res. 2018;161:73-77.
Onyeama S-JN, Hanson SJ, Dasgupta M, Baker K, Simpson PM, Punzalan RC. Central venous catheter-associated venous thromboembolism in children with hematologic malignancy. J Pediatr Hematol Oncol. 2018;40(8):e519-e524.
Schoot RA, van de Wetering MD, Stijnen T, et al. Prevalence of symptomatic and asymptomatic thrombosis in pediatric oncology patients with tunneled central venous catheters. Pediatr Blood Cancer. 2016;63(8):1438-1444.
Abedin S, Kapoor G. Peripherally inserted central venous catheters are a good option for prolonged venous access in children with cancer. Pediatr Blood Cancer. 2008;51(2):251-255.
Kanin M, Young G. Incidence of thrombosis in children with tunneled central venous access devices versus peripherally inserted central catheters (PICCs). Thromb Res. 2013;132(5):527-530.
Massicotte MP, Dix D, Monagle P, Adams M, Andrew M. Central venous catheter related thrombosis in children: analysis of the Canadian Registry of Venous Thromboembolic Complications. J Pediatr. 1998;133(6):770-776.
Close AG, Dreyzin A, Miller KD, Seynnaeve BKN, Rapkin LB. Adolescent and young adult oncology-past, present, and future. CA Cancer J Clin. 2019;69(6):485-496.
Grace RF, Deangelo DJ, Stevenson KE, et al. The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia. J Thromb Thrombolysis. 2018;45(2):306-314.
Greiner J, Schrappe M, Claviez A, et al. THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica. 2019;104(4):756-765.
O'Brien SH, Li D, Mitchell LG, et al. PREVAPIX-ALL: apixaban compared to standard of care for prevention of venous thrombosis in paediatric acute lymphoblastic leukaemia (ALL)-rationale and design. Thromb Haemost. 2019;119(5):844-853.
Cancer.org. Cancer Facts and Figures 2020. Special Section: Cancer in Adolescents and Young Adults. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/special-section-cancer-in-adolescents-and-young-adults-2020.pdf. Accessed October 25, 2020.